Filed with the SEC on · Summarized by InvestorsBot
Incyte EVP and Chief Scientific Officer Patrick A. Mayes sold 47,954 shares in open-market transactions on July 31 and August 3 at prices ranging from $119.38 to $122.19 per share, for approximately $5.73 million total. His reported holdings after the transactions ranged from 88,679 shares to 61,441 shares, with 61,441 shares reported after the August 3 sale.
Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.
Subscribe freeIncyte R&D chief sells $1.9 million in stock
Form 4 · Insider Trade · August 4, 2026
Incyte reports Q2 revenue growth and raises 2026 sales guidance
8-K · July 28, 2026
Incyte ($INCY) filed an 8‑K (Item 9.01) furnishing a press release dated Mar 25, 2026 (Exhibit 99.1) and…
8-K · March 26, 2026
Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J.
8-K · March 26, 2026
FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg…
8-K · March 6, 2026
Incyte files Form 8‑K (Item 9.01) dated Feb 10, 2026 to furnish a press release (Exhibit 99.1); Cover Page…
8-K · February 10, 2026